Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

Published:2008-09 Issue:9 Volume:10 Page:583-586
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Jurado García José Miguel,Sánchez Alfonso,Pajares Bella,Pérez Elisabeth,Alonso Lorenzo,Alba Emilio

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-008-0254-7.pdf

Reference29 articles.

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66

2. Ozols R, Bundy B, Creer B et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 17:3194–3200

3. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III trial of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312–3322

4. Ozols RF (2001) The current role of gemcitabine in ovarian cancer. Semin Oncol 28:18–24

5. Markman M, Hall J, Spitz D et al (2002) Phase II trial of weekly single agent paclitaxel in platinum/paclitaxel refractory ovarian cancer. J Clin Oncol 20:2365–2369

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”;Cancer Letters;2024-08

2. Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology;Heliyon;2024-02

3. Metronomic chemotherapy in ovarian cancer;Cancer Letters;2023-11

4. Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy;Immunotherapy;2023-04

5. Targeted therapy and molecular genetics;DiSaia and Creasman Clinical Gynecologic Oncology;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3